Loading...
•
Dec 31, 2022
LifeStance Q4 2022 Earnings Report
LifeStance reported a 21% increase in revenue, driven by increased visit volumes, and made progress in streamlining the business.
Key Takeaways
LifeStance Health Group, Inc. reported a 21% increase in fourth-quarter revenue to $229.4 million. The company's clinician base grew by 18% to 5,631, with 200 net clinician additions in the fourth quarter. The company is focused on streamlining and standardizing its business to pave the way for profitable and sustainable growth.
Fourth quarter revenue increased 21% to $229.4 million.
The clinician base increased 18% to 5,631 clinicians, including 200 net clinician adds in the fourth quarter.
Net loss of $46.7 million in the fourth quarter, primarily driven by stock and unit-based compensation.
Adjusted EBITDA of positive $10.2 million in the fourth quarter.
LifeStance
LifeStance
Forward Guidance
LifeStance expects full year 2023 revenue of $980 million to $1.02 billion, Center Margin of $270 to $290 million, and Adjusted EBITDA of $50 to $62 million.
Positive Outlook
- Expecting full year 2023 revenue of $980 million to $1.02 billion
- Expecting Center Margin of $270 to $290 million
- Expecting Adjusted EBITDA of $50 to $62 million
- The Company expects total revenue of $242 to $252 million for the first quarter of 2023
- The Company expects Center Margin of $62 to $69 million for the first quarter of 2023
Challenges Ahead
- Expecting Adjusted EBITDA of $7 to $12 million for the first quarter of 2023
- Focus remains on streamlining and standardizing our business over the next two years
- Adjusted EBITDA as a percentage of revenue decreased as a result of higher-than-expected G&A expenses in the fourth quarter
- Expecting Adjusted EBITDA of $50 to $62 million.
- Expecting full year 2023 revenue of $980 million to $1.02 billion